Introduction
============

Lung cancer, particularly non-small-cell lung cancer (NSCLC), is one of the most common malignancies and the most common cause of cancer-related mortality worldwide.[@b1-ott-9-2317] The prognosis of patients with NSCLC, especially in an advanced stage, is generally poor where the 5-year survival rate is \<10%.[@b2-ott-9-2317]

Integrins are heterodimeric cell-surface adhesion receptors generally consisting of noncovalently linked alpha and beta subunits. A total of 18 alpha and eight beta subunits with different functions are currently known.[@b3-ott-9-2317] Integrin family members participate in a variety of processes influencing the cell's biological behavior, including cell adhesion, recognition, immune response, metastasis of tumor cells as well as embryogenesis, hemostasis, and tissue repair.[@b4-ott-9-2317] Alterations in integrin expression levels can influence cancer cell adhesion, polarity, and extracellular matrix assembly, which may result in tumor metastasis.[@b5-ott-9-2317] Integrins can also interact with tyrosine kinase receptors, such as epidermal growth factor receptor (EGFR) and vascular EGFR (VEGFR), to promote cancer cell proliferation, survival, and differentiation.[@b6-ott-9-2317] EGFR mutations frequentlyoccur in patients with lung cancer, and these patients have been found to benefit from tyrosine kinase inhibitor-targeted therapy rather than first-line chemotherapy.[@b7-ott-9-2317]

There was a report that discussed the integrin profile and prognosis in NSCLC;[@b8-ott-9-2317] however, external validation and interactions of integrins within the network of integrins were not determined. The Cancer Genome Atlas (TCGA) database has been developed in recent years using a large amount of NSCLC RNAseq data as well as detailed clinical data, and this has made bioinformatic data mining convenient and reliable.[@b9-ott-9-2317] This study was aimed at determining the prognostic ability of integrins and associated genes identified through the molecular network using TCGA database analysis in NSCLC.

Materials and methods
=====================

Patients
--------

Expression data of integrins and their associated genes and relative clinical data of patients with NSCLC were available in TCGA database provided on the website of the Cancer Genomics Browser of the University of California Santa Cruz (<https://genome-cancer.ucsc.edu/>). Thirty members of the integrin family were included in our study ([Table S1](#SD1-ott-9-2317){ref-type="supplementary-material"}). There were 1,092 patients with NSCLC enrolled in TCGA database (updated on February 24, 2015) according to the parameters defined in a previous study.[@b10-ott-9-2317] Patients without fully characterized tumors, deficient overall survival (OS) data, or incomplete RNAseq information were excluded from the study. Clinicopathological characteristics, including age, sex, histology, TNM stage, American Joint Committee on Cancer stage, smoking status, and history of neoadjuvant and radiation therapy, were collected. Information on integrin family genes was also obtained from TCGA RNAseq database. Networks of integrin genes, which were independent prognostic predictors of NSCLC, were obtained from the cBioPortal website (<http://www.cbioportal.org/public-portal/cgds_r.jsp>). Network filters were set as "in the same complex" or "interacted with each other", and threshold was set as \>12% changes.

This study is based on publicly available data from TCGA database and did not involve interaction with human subjects or the use of personal identifying information. The study was approved by the Institutional Review Board of Guangqian Hospital, Quanzhou, Fujian, People's Republic of China.

Statistical analysis
--------------------

OS was defined as time from the date of diagnosis to the date of death or the last follow-up. Patients without an event of death were recorded as censored at the time of last follow-up. The R project (3.1.3) was used to perform statistical analysis. Survival curves were constructed using the Kaplan--Meier method, with log-rank tests used to assess differences between groups. Univariate and multivariate Cox proportional hazards models were used to analyze the relationship between integrin network expression and OS of patients with NSCLC in TCGA cohort. A two-sided *P*-value \<0.05 was considered statistically significant. Odds ratios with 95% confidence intervals (CIs) were calculated.

Results
=======

Clinical factors in TCGA cohorts
--------------------------------

A total of 959 patients with NSCLC, including 576 men and 383 women, from TCGA cohort were enrolled in the current study. The median age of the cohort was 67. There were 485 patients diagnosed with adenocarcinoma and 474 patients diagnosed with squamous cell carcinoma (SCC). Detailed clinicopathological data are shown in [Table 1](#t1-ott-9-2317){ref-type="table"}. The median OS in this cohort was 16.7 months.

ITGA5 and ITGB1 expressions were independent prognostic factors for OS in TCGA cohort
-------------------------------------------------------------------------------------

In univariate Cox regression analysis, *ITGA1, ITGA5, ITGA6, ITGB1, ITGB4*, and *ITGA11* were significantly associated with OS in patients with NSCLC (all *P*\<0.05, [Table 2](#t2-ott-9-2317){ref-type="table"}). In multivariate models, after adjusting for age, sex, stage, histological subtype, smoking history, neoadjuvant therapy history, and radiation therapy history, *ITGA5* (HR =1.17, 95% CI: 1.05--1.31) and *ITGB1* (HR =1.31, 95% CI: 1.10--1.55) were independent predictors of prognosis (all *P*\<0.01, [Table 2](#t2-ott-9-2317){ref-type="table"}).

We then divided TCGA cohort according to the histological subtype. In TCGA NSCLC cohort, large-cell carcinoma data were not available; therefore, we analyzed only two subgroups of adenocarcinoma and SCC. In 485 patients with adenocarcinoma, *ITGA5* (HR =1.316, 95% CI: 1.135--1.525) and *ITGB1* (HR =1.788, 95% CI: 1.399--2.286) were associated with OS in univariate analysis. However, in multivariate analysis, *ITGA6* (HR =1.208, 95% CI: 1.014--1.439) was found to be the unique, independent prognostic factor. Also, *ITGA5* (HR =1.142, 95% CI: 1.005--1.299) and *ITGB1* (HR =1.231, 95% CI: 1.006--1.507) were prognostic factors of 474 patients with SCC with univariate analysis. After adjusting for clinical factors and other integrin family members, *ITGA3* (HR =1.182, 95% CI: 1.002--1.394) was the only prognostic factor ([Table 3](#t3-ott-9-2317){ref-type="table"}).

Further studies of integrin and lymph node metastasis and distant metastasis were conducted with Spearman's correlation analysis. *ITGA3, ITGB5, ITGB6*, and *ITGB8* were associated with lymph node staging of SCC. *ITGB1* was the only factor correlated with distant metastasis in SCC. The pattern was different in adenocarcinoma. *ITGA5, ITGA7, ITGA9, ITGAD, ITGAL*, and *ITGAV* were associated with N stage, and *ITGA3, ITGB1BP3, ITGB5*, and *ITGBL1* were correlated with M stage ([Table S2](#SD2-ott-9-2317){ref-type="supplementary-material"}).

Expression levels of *ITGA5* and *ITGB1* in TCGA cohort showed nearly normal distribution (data not shown); therefore, we divided the cohort into low and high expressers according to the median expression levels of *ITGA5* and *ITGB1*. Kaplan--Meier plots demonstrated that high expressers of *ITGA5* or *ITGB1* were associated with poor OS (all *P*\<0.05, [Figure 1A and B](#f1-ott-9-2317){ref-type="fig"}). Moreover, in subgroup analysis, ITGA5 and ITGB1 were associated with poor prognosis of adenocarcinoma as well as SCC (all *P*\<0.05, [Figure 2A--D](#f2-ott-9-2317){ref-type="fig"}).

ITGA5 and ITGB1 gene cluster analysis and its association with prognosis
------------------------------------------------------------------------

Although difference in integrin expression pattern existed between SCC and adenocarcinoma of lung cancer, *ITGA5* and *ITGB1* were more important genes because a selective inhibitor cilengitide has been developed.[@b11-ott-9-2317] Therefore, the gene networks of *ITGA5* and *ITGB1* were studied. Three situations were selected for building the interaction network of *ITGA5* and *ITGB1* ([Figure 3](#f3-ott-9-2317){ref-type="fig"}). They were stated as "react with", "state change" (cut-point was set at 12%[@b12-ott-9-2317]), and "in same component". A total of 33 genes were listed in the *ITGA5* or *ITGB1* gene networks ([Table S3](#SD3-ott-9-2317){ref-type="supplementary-material"}). In the univariate Cox regression model, *PLAUR, PRKACA, ILK, YWHAZ, SPP1, PXN, LAMC1, TLN1*, and *CD9* expressions were indicated as predictive of prognosis in patients with NSCLC in TCGA cohort (*P*\<0.05, [Table 4](#t4-ott-9-2317){ref-type="table"}). Multivariate analysis, after adjusting for all potential prognostic factors, indicated that *PLAUR* (HR =1.16, 95% CI: 1.04--1.30), *ILK* (HR =1.27, 95% CI: 1.00--1.60), *SPP1* (HR =1.08, 95% CI: 1.02--1.15), *PXN* (HR =1.25, 95% CI: 1.06--1.48), and *CD9* (HR =0.83, 95% CI: 0.74--0.94) were independent predictors of OS (all *P*\<0.05, [Table 4](#t4-ott-9-2317){ref-type="table"}).

Discussion
==========

Dingemans et al had reported that ITGA5 and ITGB1 were prognostic factors in the early stage of NSCLC.[@b8-ott-9-2317] We validated their findings in a large cohort from TCGAdatabase. Aside from *ITGA5* and *ITGB1, PLAUR, ILK, SPP1, PXN*, and *CD9* were identified as independent predictors of OS in patients with NSCLC using gene network analysis.

As cell adhesion proteins, integrins play an important role in the cellular and extracellular environment to regulate attachment, survival, and motility.[@b13-ott-9-2317] Integrins are communicators between the cell and the extracellular environment.[@b5-ott-9-2317] Integrins can activate growth receptors and downstream cellular signals,[@b6-ott-9-2317] leading to cancer growth, metastasis, tumor angiogenesis, and resistance to radiotherapy and chemotherapy.[@b14-ott-9-2317],[@b15-ott-9-2317] Integrin expression levels have been reported to correlate with prognosis in glioblastoma, cervical squamous cell cancer, ovarian cancer, gastric cancer, and melanoma.[@b13-ott-9-2317],[@b16-ott-9-2317]--[@b23-ott-9-2317] As drug targets, integrin inhibition enhances the cytotoxic efficacy of radiation and chemotherapy.[@b24-ott-9-2317],[@b25-ott-9-2317] Several integrin inhibitors have entered clinical trials as cancer therapy agents.[@b26-ott-9-2317]

Previous studies have reported an association between increased integrin alpha 5 expression and poor outcome in NSCLC.[@b8-ott-9-2317],[@b27-ott-9-2317] More specifically, Adachi et al found that inlymph-node-negative patients with NSCLC, high ITGA5 expressers had a significantly worse 5-year survival. It was suggested that tumors that express high levels of ITGA5 were more prone to metastasis or had undetectable micrometastases at the time of surgery.[@b27-ott-9-2317] Other studies have also pointed to a relationship between ITGA5 and tumor metastasis. Valastyan et al reported that the downregulation of ITGA5 by miR-31 decreased breast cancer metastasis in vivo.[@b28-ott-9-2317] MiR-148b-mediated ITGA5 inhibition could also decrease lung metastasis formation.[@b29-ott-9-2317]

The prognostic value of ITGB1 in NSCLC has been reported,[@b30-ott-9-2317] and it was shown to be correlated with lymph node metastasis.[@b31-ott-9-2317] ITGB1 inhibition has been shown to decrease lung cancer invasion and metastasis in vitro and in vivo.[@b32-ott-9-2317] Our work indicates a certain correlation between NSCLC outcome and the integrin gene family; however, the mechanism, which is likely to be complex, remains unclear. Further study is required.

Our study tried to answer several questions left unanswered in previous studies. We found that integrins were differently expressed in SCC and adenocarcinoma of lung cancer. The independent factors were different as well. They were ITGA6 in adenocarcinoma and ITGA3 in SCC. The diversity of independent prognostic factors of NSCLC was possible due to different expression patterns of SCC and adenocarcinoma. A previous study had shown that ITGA3 was upregulated in adenocarcinoma but not in SCC;[@b33-ott-9-2317] however, we found that the upregulation of *ITGA3* in SCC indicated poor prognosis. In adenocarcinoma, the *ITGA3* levels were relatively high with minor diversity. Another controversial topic is integrin and the metastatic potential of NSCLC. In our study, different subtypes of NSCLC demonstrated diverse integrins that were associated with metastasis. Only ITGA3 and ITGA5 were associated with NSCLC metastasis. ITGA5 was associated with lymph node metastasis of adenocarcinoma, which was possibly due to the role of ITGA5 in activating endothelial cells during tumor angiogenesis.[@b8-ott-9-2317] Furthermore, our study identified a new set of genes as NSCLC biomarkers or even therapeutic targets through *ITGA5* and *ITGB1* network analysis. Suppression PLAUR expression could decrease lung cancer lymph node metastasis.[@b34-ott-9-2317] ILK binds the cytoplasmic domain of beta integrins and regulates the integrin-mediated signal transduction. Its activity is important in epithelial-to-mesenchymal transition, and the overexpression of ILK has been implicated in tumor growth and metastasis via nuclear factor-κB signaling.[@b35-ott-9-2317] SPP1 encodes for the protein osteopontin, which is principally expressed in NSCLC tissues. SPP1 may be tightly regulated by the Ras oncogene[@b36-ott-9-2317] and is important in VEGF-mediated tumor angiogenesis.[@b37-ott-9-2317] PXN, which encodes for the protein paxillin, has been shown to be regulated by miR-218[@b38-ott-9-2317] and could make EGFR-mutant lung cancers resistant to tyrosine kinase inhibitor via modulating the stability of BIM and Mcl-1 proteins.[@b39-ott-9-2317]

Different from the above four genes, *CD9* was a favorable factor in NSCLC outcome. This is supported by previous studies that showed that the low expression of CD9 may contribute to the early recurrence of NSCLC.[@b40-ott-9-2317] These studies suggested that the influence of integrins on the outcome of NSCLC might be via the regulation of epithelial-to-mesenchymal transition, tumor invasion, angiogenesis, and metastasis. These consistent results demonstrated that our method was applicable for detecting new prognostic indicators or even therapeutic targets.

In the study, all information was obtained from a large population with long-time follow-up and standard specimen collection and sequencing. The results were open-access, repeatable, and with high statistical power. However, there were certain limitations to our study. Although there was external validation previously,[@b8-ott-9-2317] we analyzed the correlationamong integrins and network gene expression and NSCLC OS only in TCGA cohort. The prognosis of NSCLC is affected by many factors, such as comorbidity, tumor stage, surgical performance, and response to radiation therapy and chemotherapy, so a single biomarker is not enough. In addition, information on ethnicity was not available in TCGA database. In conclusion, further mechanistic research will be required to understand in more detail the integrin family and its role in patients with NSCLC.

Conclusion
==========

*ITGA5* and *ITGB1* were identified as independent prognostic integrin markers associated with OS in NSCLC, and several outcome-related genes were determined through gene cluster analysis. This method could act as a tool to uncover more prognostic-associated genes and therapeutic targets in NSCLC.

Supplementary materials
=======================

###### 

Gene IDs of integrin family and related genes

  Official gene symbol   Full name                                                                                               UniGene
  ---------------------- ------------------------------------------------------------------------------------------------------- -----------
  ITGA1                  Integrin, alpha 1                                                                                       Hs.644352
  ITGA2                  Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)                                            Hs.482077
  ITGA2B                 Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41)                        Hs.411312
  ITGA3                  Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)                                    Hs.265829
  ITGA4                  Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)                                    Hs.440955
  ITGA5                  Integrin, alpha 5 (fibronectin receptor, alpha polypeptide)                                             Hs.505654
  ITGA6                  Integrin, alpha 6                                                                                       Hs.133397
  ITGA7                  Integrin, alpha 7                                                                                       Hs.524484
  ITGA8                  Integrin, alpha 8                                                                                       Hs.171311
  ITGA9                  Integrin, alpha 9                                                                                       Hs.113157
  ITGA10                 Integrin, alpha 10                                                                                      Hs.158237
  ITGA11                 Integrin, alpha 11                                                                                      Hs.436416
  ITGAD                  Integrin, alpha D                                                                                       Hs.679163
  ITGAE                  Integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1, alpha polypeptide)                Hs.513867
  ITGAL                  Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1, alpha polypeptide)   Hs.174103
  ITGAM                  Integrin, alpha M (complement component 3 receptor 3 subunit)                                           Hs.172631
  ITGAV                  Integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51)                               Hs.436873
  ITGAX                  Integrin, alpha X (complement component 3 receptor 4 subunit)                                           Hs.248472
  ITGB1                  Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)            Hs.643813
  ITGB1BP1               Integrin, beta 1 binding protein 1                                                                      Hs.467662
  ITGB1BP2               Integrin, beta 1 binding protein (melusin) 2                                                            Hs.109999
  ITGB1BP3               Integrin, beta 1 binding protein 3 (nicotinamide riboside kinase 2)                                     Hs.135458
  ITGB2                  Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit)                                      Hs.375957
  ITGB3                  Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)                                             Hs.218040
  ITGB3BP                Integrin, beta 3 binding protein (beta 3-endonexin)                                                     Hs.166539
  ITGB4                  Integrin, beta 4                                                                                        Hs.632226
  ITGB5                  Integrin, beta 5                                                                                        Hs.536663
  ITGB6                  Integrin, beta 6                                                                                        Hs.470399
  ITGB7                  Integrin, beta 7                                                                                        Hs.654470
  ITGBL1                 Integrin, beta-like 1 (with EGF-like repeat domains)                                                    Hs.696554

###### 

Spearman's correlation analysis of integrin family and N stage and M stage of NSCLC

  Gene       Squamous cell carcinoma   Adenocarcinoma                                              
  ---------- ------------------------- ---------------- -------- ------- -------- ------- -------- -------
  ITGA1      0.016                     0.733            0.072    0.153   0.065    0.156   −0.025   0.643
  ITGA2      −0.047                    0.308            0.039    0.443   0.074    0.105   −0.015   0.779
  ITGA2B     0.034                     0.469            0.006    0.911   −0.070   0.129   −0.003   0.956
  ITGA3      −0.098                    0.035            0.041    0.412   0.051    0.264   −0.107   0.047
  ITGA4      0.013                     0.780            0.001    0.988   −0.068   0.140   −0.084   0.118
  ITGA5      −0.068                    0.142            0.049    0.328   0.113    0.014   −0.019   0.721
  ITGA6      −0.033                    0.471            −0.032   0.532   0.003    0.943   0.030    0.574
  ITGA7      −0.016                    0.738            −0.070   0.166   −0.134   0.003   −0.035   0.514
  ITGA8      −0.052                    0.261            0.064    0.205   −0.086   0.062   −0.048   0.370
  ITGA9      −0.028                    0.546            −0.018   0.714   −0.132   0.004   −0.035   0.517
  ITGA10     −0.055                    0.237            0.002    0.972   −0.083   0.070   0.080    0.139
  ITGA11     0.017                     0.709            0.048    0.343   0.075    0.105   −0.097   0.072
  ITGAD      −0.032                    0.489            −0.058   0.248   −0.154   0.001   −0.053   0.326
  ITGAE      0.090                     0.051            −0.084   0.097   −0.047   0.304   −0.043   0.427
  ITGAL      0.012                     0.790            −0.056   0.269   −0.102   0.026   −0.069   0.203
  ITGAM      −0.027                    0.559            −0.036   0.473   −0.037   0.422   −0.085   0.116
  ITGAV      −0.088                    0.058            0.089    0.077   0.092    0.045   −0.070   0.192
  ITGAX      −0.037                    0.420            −0.004   0.929   −0.072   0.116   −0.050   0.353
  ITGB1      −0.040                    0.384            0.111    0.028   0.046    0.319   0.000    0.993
  ITGB1BP1   0.080                     0.083            0.068    0.179   0.054    0.242   0.006    0.917
  ITGB1BP3   −0.026                    0.577            −0.077   0.125   −0.077   0.095   0.128    0.018
  ITGB1BP2   −0.089                    0.054            −0.014   0.776   −0.011   0.814   −0.088   0.105
  ITGB2      0.012                     0.802            −0.062   0.220   −0.027   0.562   −0.099   0.067
  ITGB3      −0.079                    0.086            0.035    0.488   0.071    0.122   −0.071   0.187
  ITGB3BP    −0.042                    0.366            −0.019   0.702   −0.021   0.641   0.097    0.072
  ITGB4      0.007                     0.872            0.062    0.218   0.076    0.096   −0.040   0.465
  ITGB5      −0.094                    0.041            0.059    0.245   0.022    0.626   −0.114   0.035
  ITGB6      −0.140                    0.002            0.080    0.112   −0.003   0.953   −0.033   0.548
  ITGB7      0.016                     0.734            −0.083   0.099   −0.063   0.173   −0.083   0.126
  ITGB8      −0.116                    0.012            0.029    0.566   0.009    0.852   −0.036   0.502
  ITGBL1     −0.005                    0.914            0.082    0.106   −0.070   0.126   −0.115   0.032

**Note:**

Bold type indicates statistical significance.

**Abbreviations:** M, M stage; N, N stage; NSCLC, non-small-cell lung cancer.

###### 

Gene IDs of ITGA5 and ITGB1 network genes

  Official gene symbol   Full name                                                           UniGene
  ---------------------- ------------------------------------------------------------------- -----------
  ABI1                   abl-interactor 1                                                    Hs.508148
  ADAM15                 ADAM metallopeptidase domain 15                                     Hs.312098
  ARHGAP5                Rho GTPase-activating protein 5                                     Hs.592313
  CD81                   CD81 molecule                                                       Hs.54457
  CD9                    CD9 molecule                                                        Hs.114286
  COL18A1                Collagen, type XVIII, alpha 1                                       Hs.517356
  EGFR                   Epidermal growth factor receptor                                    Hs.488293
  EPS8                   Epidermal growth factor receptor pathway substrate 8                Hs.591160
  ERBB2                  v-erb-b2 erythroblastic leukemia viral oncogene homolog 2           Hs.446352
  GIPC1                  GIPC PDZ domain containing family, member 1                         Hs.655012
  IGF1R                  Insulin-like growth factor 1 receptor                               Hs.643120
  ILK                    Integrin-linked kinase                                              Hs.706355
  LAMB2                  Laminin, beta 2 (laminin S)                                         Hs.439726
  LAMC1                  Laminin, gamma 1 (formerly LAMB2)                                   Hs.609663
  PLAUR                  Plasminogen activator, urokinase receptor                           Hs.466871
  PRKACA                 Protein kinase, cAMP-dependent, catalytic, alpha                    Hs.631630
  PRKAR1A                Protein kinase, cAMP-dependent, regulatory, type I, alpha           Hs.280342
  PRKAR1B                Protein kinase, cAMP-dependent, regulatory, type I, beta            Hs.520851
  PRKCA                  Protein kinase C, alpha                                             Hs.531704
  PTK2                   PTK2 protein tyrosine kinase 2                                      Hs.395482
  PTK2B                  PTK2B protein tyrosine kinase 2 beta                                Hs.491322
  PTPRA                  Protein tyrosine phosphatase, receptor type, A                      Hs.269577
  PXN                    Paxillin                                                            Hs.446336
  RAC1                   Ras-related C3 botulinum toxin substrate 1                          Hs.413812
  RPS6KB1                Ribosomal protein S6 kinase, 70 kDa, polypeptide 1                  Hs.463642
  SDC2                   Syndecan 2                                                          Hs.1501
  SDC4                   Syndecan 4                                                          Hs.632267
  SPP1                   Secreted phosphoprotein 1                                           Hs.313
  SRC                    v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)   Hs.195659
  TLN1                   Talin 1                                                             Hs.471014
  VEGFA                  Vascular endothelial growth factor A                                Hs.73793
  VLDLR                  Very low density lipoprotein receptor                               Hs.370422
  YWHAZ                  Tryptophan 5-monooxygenase activation protein, zeta polypeptide     Hs.492407

**Abbreviation:** EGFR, epidermal growth factor receptor.
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![Kaplan--Meier plots of survival are shown according to ITGA5 and ITGB1 expression.\
**Notes:** (**A** and **B**) Kaplan--Meier estimates of OS are shown according to the expression level of ITGA5 and ITGB1.\
**Abbreviations:** NSCLC, non-small-cell lung cancer; OS, overall survival.](ott-9-2317Fig1){#f1-ott-9-2317}

![Kaplan--Meier estimates of overall survival according to ITGA5 expression, ITGB1 expression, and pathological histology.\
**Notes:** (**A** and **B**) Kaplan--Meier estimates of OS were plotted according to ITGA5 expression in adenocarcinoma and squamous cell carcinoma. (**C** and **D**) Kaplan--Meier estimates of OS were demonstrated according to ITGB1 expression in adenocarcinoma and squamous cell carcinoma.\
**Abbreviation:** OS, overall survival.](ott-9-2317Fig2){#f2-ott-9-2317}

![Interaction network building of ITGA5 and ITGB1.\
**Notes:** The situations selected for building the networks were stated as "react with" (purple line), "in same component" (brown line), and "state change" (green arrow). The cut-off point of state change was set as 12%. (**A**) The network of ITGA5 and (**B**) the network of ITGB1.](ott-9-2317Fig3){#f3-ott-9-2317}

###### 

Clinical characteristics of patients with NSCLC in TCGA cohort

  Variables                        Number   \%
  -------------------------------- -------- -------------
  Number of patients               959      
  Age, median (range)              67       (38--90)
  Sex                                       
   Male                            576      60.10
   Female                          383      39.90
  Histology                                 
   Adenocarcinoma                  485      50.60
   Squamous cell carcinoma         474      49.40
  pT                                        
   T1                              270      28.20
   T2                              538      56.10
   T3                              110      11.50
   T4                              39       4.10
   Tx                              2        0.20
  N                                         
   N0                              612      63.80
   N1                              216      22.50
   N2                              108      11.30
   N3                              7        0.70
   Nx                              16       1.70
  M                                         
   M0                              707      73.70
   M1                              31       3.20
   Mx                              221      23.00
  Stage                                     
   I                               495      51.60
   II                              269      28.10
   III                             163      17.00
   IV                              32       3.30
  Smoking status                            
   Nonsmoker                       86       9.00
   Reformed smoker                 608      63.40
   Current smoker                  244      25.40
  History of neoadjuvant therapy            
   Yes                             10       1.00
   No                              949      99.00
  History of radiation therapy              
   Yes                             94       9.80
   No                              641      66.80
   Undefined                       224      23.40
  Median OS in months (range)      16.7     (0.5--83.3)

**Note:** Figures are expressed as percentage unless range (shown in parentheses).

**Abbreviations:** M, M stage; N, N stage; NSCLC, non-small-cell lung cancer; OS, overall survival; pT, pathological T stage; TCGA, The Cancer Genome Atlas.

###### 

Univariate and multivariate Cox proportional hazards analysis of integrin expression and overall survival for patients with NSCLC in TCGA cohort

  Gene         Univariate   Multivariate[a](#tfn3-ott-9-2317){ref-type="table-fn"}                                                                            
  ------------ ------------ -------------------------------------------------------- -------------------------------------------------- ------ -------------- --------------------------------------------------
  *ITGA8*      1.01         (0.96--1.06)                                             0.736                                                                    
  *ITGA9*      0.99         (0.93--1.06)                                             0.830                                                                    
  *ITGA1*      1.11         (1.01--1.23)                                             0.039[\*](#tfn4-ott-9-2317){ref-type="table-fn"}   1.10   (0.97--1.25)   0.132
  *ITGA2*      1.07         (0.99--1.15)                                             0.070                                              1.01   (0.93--1.11)   0.760
  *ITGA3*      1.06         (0.98--1.15)                                             0.148                                                                    
  *ITGA4*      1.00         (0.91--1.10)                                             0.989                                                                    
  *ITGA5*      1.21         (1.10--1.33)                                             0.000[\*](#tfn4-ott-9-2317){ref-type="table-fn"}   1.17   (1.05--1.31)   0.005[\*](#tfn4-ott-9-2317){ref-type="table-fn"}
  *ITGA6*      1.09         (1.03--1.16)                                             0.005[\*](#tfn4-ott-9-2317){ref-type="table-fn"}   1.09   (0.98--1.22)   0.123
  *ITGA7*      0.99         (0.91--1.09)                                             0.911                                                                    
  *ITGAX*      1.00         (0.91--1.08)                                             0.926                                                                    
  *ITGAV*      1.10         (0.97--1.24)                                             0.127                                                                    
  *ITGAL*      0.96         (0.89--1.04)                                             0.338                                                                    
  *ITGAM*      1.04         (0.97--1.12)                                             0.298                                                                    
  *ITGA2B*     0.95         (0.88--1.01)                                             0.109                                                                    
  *ITGB1BP1*   0.98         (0.80--1.21)                                             0.868                                                                    
  *ITGB1BP3*   0.94         (0.80--1.10)                                             0.427                                                                    
  *ITGB1BP2*   0.98         (0.88--1.08)                                             0.637                                                                    
  *ITGAD*      0.94         (0.87--1.01)                                             0.091                                              0.94   (0.86--1.02)   0.127
  *ITGAE*      0.97         (0.83--1.13)                                             0.683                                                                    
  *ITGBL1*     1.05         (0.98--1.12)                                             0.149                                                                    
  *ITGB3BP*    0.95         (0.82--1.11)                                             0.550                                                                    
  *ITGB1*      1.41         (1.21--1.64)                                             0.000[\*](#tfn4-ott-9-2317){ref-type="table-fn"}   1.31   (1.10--1.55)   0.002[\*](#tfn4-ott-9-2317){ref-type="table-fn"}
  *ITGB3*      1.03         (0.97--1.10)                                             0.271                                                                    
  *ITGB5*      1.11         (0.98--1.27)                                             0.102                                                                    
  *ITGB4*      1.11         (1.03--1.19)                                             0.006[\*](#tfn4-ott-9-2317){ref-type="table-fn"}   1.06   (0.97--1.17)   0.218
  *ITGB7*      1.00         (0.90--1.10)                                             0.966                                                                    
  *ITGB6*      1.06         (0.99--1.13)                                             0.089                                              1.06   (0.98--1.15)   0.127
  *ITGB8*      1.00         (0.95--1.05)                                             0.932                                                                    
  *ITGA10*     1.00         (0.93--1.09)                                             0.914                                                                    
  *ITGA11*     1.07         (1.01--1.14)                                             0.032[\*](#tfn4-ott-9-2317){ref-type="table-fn"}   1.07   (1.00--1.16)   0.051
  *ITGB2*      1.01         (0.93--1.09)                                             0.833                                                                    

**Notes:**

Multivariate Cox regression was adjusted for clinical factors (age, sex stage, histological subtype, smoking history, neoadjuvant therapy history, and radiation therapy history).

Indicates statistical significance.

**Abbreviations:** CI, confidence interval; NSCLC, non-small-cell lung cancer; TCGA, The Cancer Genome Atlas; HR, hazard ratio.

###### 

Univariate and multivariate Cox proportional hazards analysis of integrin expression and overall survival for patients with adenocarcinoma and squamous cell carcinoma of lung cancer in TCGA cohort

  Gene         Adenocarcinoma (N=485)   Squamous cell carcinoma (N=474)                                                                                                                                                                                                                                        
  ------------ ------------------------ --------------------------------- -------------------------------------------------- ------- ---------------- -------------------------------------------------- ------- ----------------- -------------------------------------------------- ------- ---------------- --------------------------------------------------
  *ITGA1*      1.138                    (0.967--1.340)                    0.120                                                                                                                          1.172   (1.010--1.360)    0.037[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   1.032   (0.755--1.375)   0.830
  *ITGA2*      1.123                    (1.019--1.238)                    0.019[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   1.044   (0.901--1.210)   0.565                                              0.983   (0.870--1.109)    0.776                                                                       
  *ITGA2B*     0.920                    (0.836--1.012)                    0.087                                              0.961   (0.855--1.079)   0.502                                              0.973   (0.879--1.078)    0.604                                                                       
  *ITGA3*      0.964                    (0.832--1.117)                    0.623                                                                                                                          1.160   (1.043--1.290)    0.006[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   1.182   (1.002--1.394)   0.047[\*](#tfn7-ott-9-2317){ref-type="table-fn"}
  *ITGA4*      0.904                    (0.777--1.051)                    0.189                                                                                                                          1.079   (0.955--1.218)    0.221                                                                       
  *ITGA5*      1.316                    (1.135--1.525)                    0.000[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   1.241   (0.981--1.570)   0.072                                              1.142   (1.005--1.299)    0.042[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   1.053   (0.855--1.297)   0.626
  *ITGA6*      1.349                    (1.183--1.537)                    0.000[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   1.208   (1.014--1.439)   0.034[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   1.046   (0.926--1.183)    0.470                                                                       
  *ITGA7*      0.899                    (0.781--1.034)                    0.135                                                                                                                          1.097   (0.971--1.240)    0.136                                                                       
  *ITGA8*      0.950                    (0.880--1.026)                    0.190                                                                                                                          1.080   (1.004--1.161)    0.040[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   1.052   (0.937--1.181)   0.391
  *ITGA9*      0.891                    (0.801--0.990)                    0.032[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   0.934   (0.820--1.063)   0.301                                              1.102   (1.004--1.209)    0.042[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   1.015   (0.877--1.173)   0.846
  *ITGA10*     1.023                    (0.913--1.146)                    0.694                                                                                                                          1.018   (0.902--1.150)    0.768                                                                       
  *ITGA11*     1.114                    (1.012--1.227)                    0.028[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   1.060   (0.926--1.214)   0.395                                              1.046   (0.967--1.132)    0.264                                                                       
  *ITGAD*      0.867                    (0.772--0.974)                    0.016[\*](#tfn7-ott-9-2317){ref-type="table-fn"}                                                                               0.999   (0.906--1.101)    0.981                                                                       
  *ITGAE*      0.927                    (0.740--1.160)                    0.507                                                                                                                          0.996   (0.803--1.236)    0.974                                                                       
  *ITGAL*      0.846                    (0.741--0.965)                    0.013[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   0.836   (0.638--1.096)   0.194                                              1.043   (0.945--1.152)    0.399                                                                       
  *ITGAM*      0.962                    (0.860--1.075)                    0.491                                                                                                                          1.130   (1.020--1.252)    0.019[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   1.092   (0.942--1.266)   0.241
  *ITGAV*      1.235                    (1.027--1.486)                    0.025[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   0.964   (0.738--1.259)   0.788                                              0.998   (0.845--1.177)    0.978                                                                       
  *ITGAX*      0.902                    (0.796--1.022)                    0.106                                                                                                                          1.097   (0.974--1.235)    0.127                                                                       
  *ITGB1*      1.788                    (1.399--2.286)                    0.000[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   1.191   (0.822--1.724)   0.356                                              1.231   (1.006--1.507)    0.044[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   0.964   (0.697--1.333)   0.824
  *ITGB1BP1*   1.105                    (0.807--1.512)                    0.534                                                                                                                          0.836   (0.619--1.131)    0.245                                                                       
  *ITGB1BP3*   0.834                    (0.659--1.055)                    0.131                                                                                                                          1.155   (0.920--1.450)    0.216                                                                       
  *ITGB1BP2*   0.985                    (0.841--1.152)                    0.846                                              0.981   (0.843--1.141)   0.801                                              0.978   (0.855--1.119)    0.751                                                                       
  *ITGB2*      0.947                    (0.837--1.072)                    0.392                                                                                                                          1.089   (0.969--1.223)    0.152                                                                       
  *ITGB3*      1.023                    (0.932--1.121)                    0.636                                                                                                                          1.081   (0.986--1.185)    0.098                                              0.890   (0.747--1.060)   0.193
  *ITGB3BP*    1.059                    (0.864--1.297)                    0.583                                                                                                                          0.828   (0.658--1.042)    0.108                                                                       
  *ITGB4*      1.203                    (1.071--1.352)                    0.002[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   1.029   (0.905--1.170)   0.664                                              1.042   (0.927--1.172)    0.488                                                                       
  *ITGB5*      1.200                    (0.962--1.498)                    0.106                                                                                                                          1.063   (0.899 --1.256)   0.474                                                                       
  *ITGB6*      1.002                    (0.883--1.138)                    0.971                                                                                                                          1.104   (1.014--1.202)    0.022[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   1.019   (0.917--1.133)   0.720
  *ITGB7*      0.884                    (0.766--1.021)                    0.094                                              0.982   (0.755--1.278)   0.894                                              1.117   (0.977--1.278)    0.105                                                                       
  *ITGB8*      1.032                    (0.957--1.114)                    0.412                                                                                                                          0.903   (0.816--0.999)    0.047[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   0.909   (0.815--1.013)   0.083
  *ITGBL1*     1.018                    (0.904--1.148)                    0.765                                                                                                                          1.090   (1.000--1.188)    0.049[\*](#tfn7-ott-9-2317){ref-type="table-fn"}   1.031   (0.897--1.185)   0.670

**Notes:**

Multivariate Cox regression was adjusted for clinical factors (age, sex, stage, smoking history, neoadjuvant therapy history, and radiation therapy history).

Indicates statistical significance.

**Abbreviations:** CI, confidence interval; TCGA, The Cancer Genome Atlas; HR, hazard ratio.

###### 

Univariate and multivariate Cox proportional hazards analysis of integrin-related gene expression and overall survival for patients with NSCLC

  Gene      Univariate   Multivariate[a](#tfn9-ott-9-2317){ref-type="table-fn"}                                                                             
  --------- ------------ -------------------------------------------------------- --------------------------------------------------- ------ -------------- ---------------------------------------------------
  RAC1      1.10         (0.88--1.36)                                             0.395                                                                     
  PLAUR     1.16         (1.05--1.28)                                             0.003[\*](#tfn10-ott-9-2317){ref-type="table-fn"}   1.16   (1.04--1.30)   0.010[\*](#tfn10-ott-9-2317){ref-type="table-fn"}
  PRKACA    0.77         (0.60--0.98)                                             0.036[\*](#tfn10-ott-9-2317){ref-type="table-fn"}   0.83   (0.63--1.10)   0.196
  PRKAR1A   1.06         (0.86--1.31)                                             0.591                                                                     
  PRKAR1B   1.08         (0.94--1.24)                                             0.254                                                                     
  PTK2      1.10         (0.89--1.37)                                             0.366                                                                     
  ERBB2     0.96         (0.86--1.07)                                             0.465                                                                     
  ADAM15    0.99         (0.86--1.15)                                             0.935                                                                     
  LAMB2     1.01         (0.90--1.14)                                             0.855                                                                     
  ABI1      1.02         (0.83--1.24)                                             0.886                                                                     
  PTPRA     1.12         (0.89--1.40)                                             0.324                                                                     
  ARHGAP5   0.93         (0.77--1.12)                                             0.437                                                                     
  EPS8      0.98         (0.90--1.08)                                             0.707                                                                     
  PRKCA     1.06         (0.96--1.16)                                             0.241                                                                     
  ILK       1.22         (1.00--1.47)                                             0.046[\*](#tfn10-ott-9-2317){ref-type="table-fn"}   1.27   (1.00--1.60)   0.049[\*](#tfn10-ott-9-2317){ref-type="table-fn"}
  SRC       1.11         (0.93--1.33)                                             0.246                                                                     
  CD81      1.01         (0.84--1.21)                                             0.903                                                                     
  YWHAZ     1.32         (1.10--1.59)                                             0.003[\*](#tfn10-ott-9-2317){ref-type="table-fn"}   1.20   (0.96--1.51)   0.113
  IGF1R     1.07         (0.97--1.18)                                             0.186                                                                     
  SPP1      1.09         (1.04--1.15)                                             0.001[\*](#tfn10-ott-9-2317){ref-type="table-fn"}   1.08   (1.02--1.15)   0.012[\*](#tfn10-ott-9-2317){ref-type="table-fn"}
  PXN       1.31         (1.13--1.51)                                             0.000[\*](#tfn10-ott-9-2317){ref-type="table-fn"}   1.25   (1.06--1.48)   0.009[\*](#tfn10-ott-9-2317){ref-type="table-fn"}
  PTK2B     0.92         (0.82--1.05)                                             0.212                                                                     
  LAMC1     1.19         (1.03--1.37)                                             0.020[\*](#tfn10-ott-9-2317){ref-type="table-fn"}   1.12   (0.94--1.33)   0.197
  VLDLR     0.98         (0.90--1.07)                                             0.662                                                                     
  RPS6KB1   1.04         (0.82--1.31)                                             0.767                                                                     
  SDC2      1.02         (0.94--1.11)                                             0.628                                                                     
  SDC4      1.04         (0.93--1.16)                                             0.506                                                                     
  TLN1      1.15         (0.98--1.35)                                             0.079[\*](#tfn10-ott-9-2317){ref-type="table-fn"}   1.19   (0.99--1.44)   0.071
  VEGFA     0.99         (0.89--1.11)                                             0.929                                                                     
  EGFR      1.05         (0.98--1.12)                                             0.134                                                                     
  CD9       0.92         (0.84--1.00)                                             0.055[\*](#tfn10-ott-9-2317){ref-type="table-fn"}   0.83   (0.74--0.94)   0.003[\*](#tfn10-ott-9-2317){ref-type="table-fn"}
  COL18A1   1.08         (0.98--1.20)                                             0.137                                                                     
  GIPC1     1.01         (0.86--1.17)                                             0.925                                                                     

**Notes:**

Multivariate Cox regression was adjusted for clinical factors (age, sex, stage, histological subtype, smoking history, neoadjuvant therapy history, and radiation therapy history).

Indicates statistical significance.

**Abbreviations:** CI, confidence interval; EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; HR, hazard ratio.
